Medifron DBT Co., Ltd. announced that it expects to receive KRW 8 billion in funding
November 30, 2020
Share
Medifron DBT Co., Ltd. (KOSDAQ:A065650) announced a private placement of series 9 domestic unregistered non-guaranteed private convertible bond for gross proceeds of KRW 8,000,000,000 on November 30, 2020. The transaction will include participation from new investor J&Giant Spice Private Equity Partnership. The bonds carry 0% coupon rate, 0% yield to maturity, will mature on December 4, 2023, and are 100% convertible into 1,777,777 common shares of the company representing 4.78% stake, at a fixed conversion price of KRW 4,500 per share from December 4, 2021 till November 4, 2024. The payment date for the bonds is December 4, 2020. The transaction has been approved by the board of directors of the company.
Hyper Corporation Inc, formerly Medifron DBT Co Ltd, is a Korea-based company primarily engaged in the manufacture and sale of information and communication devices. The Company operates through three segments. The Information and Communication Technology Business segment is engaged in the manufacture and sale of gaming mice, gaming monitors, televisions, routers, and gaming devices. The Home Meal Replacement segment is engaged in the manufacture and supply of convenient meals. The New Drug Business segment is engaged in the development and sales of Alzheimer's treatments, non-narcotic painkillers, and early diagnosis kits for dementia.
HYPER CORPORATION INC. 
